AstraZeneca Didn't Deserve Seroquel Extension, DC Circ. Says
The D.C. Circuit on Friday rejected AstraZeneca PLC's bid to overturn the U.S. Food and Drug Administration's approval of generic versions of the antipsychotic drug Seroquel, ruling that the drugmaker wasn't...To view the full article, register now.
Already a subscriber? Click here to view full article